We evaluated 30 consecutive patients and 48 age- and sex-matched controls to explore the possibility of a pathogenic contribution by plasma endothelin-1 in the cardiac expression of systemic sclerosis. Venous plasma endothelin-1 was measured by radio-immunoassay and left ventricular function by echocardiography. The patient group had elevated plasma endothelin-1 (2.6±0.2 vs. 1.8±0.1 pmol/l, P<0.001), but endothelin-1 was not related to age, heart rate, blood pressure, total peripheral resistance, disease duration or systemic sclerosis score. Endothelin-1 was related to left ventricular hypertrophy in terms of septal thickness (r=0.33, P<0.01) and left ventricular mass index (r=0.32, P<0.01). Plasma endothelin-1 was further related to measures indicating reduced left ventricular filling; left atrial emptying index (r=-0.50, P<0.0005), the first third filling fraction (r=- 0.31, P<0.05) and the time velocity integral of Doppler early/late filling velocity (r=0.40, P<0.001). Furthermore, circulating endothelin-1 was related to impaired left ventricular contractility as estimated by pre-ejection period/left ventricular ejection time (r=0.32, P<0.01) and end-systolic wall stress/volume index (r=-0.30, P<0.05). We conclude that plasma endothelin-1 is elevated in relation to the degree of left ventricular hypertrophy, diastolic dysfunction and impaired contractility in systemic sclerosis. It may be of pathogenic importance to the cardiac involvement in systemic sclerosis which is not mediated via an increase in systemic blood pressure. It is not yet clear whether our findings are exclusive to systemic sclerosis patients or represent a generalized phenomenon in patients with impaired left ventricular function.
- Atrial natriuretic peptide
- Systemic sclerosis
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine